HOOKIPA Pharma to Participate in Upcoming H.C. Wainwright Global Life Sciences Conference
March 03 2021 - 7:00AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics based on its proprietary
arenavirus platform, today announced that HOOKIPA’s management team
will participate in the upcoming H.C. Wainwright Global Life
Sciences Conference held virtually from March 9-10, 2021:
Presentation: The conference is
being conducted in a virtual format and a webcast of the
presentation will become available on Tuesday, March 09, 2021 at
7:00 AM ET
The webcast of the presentation will be
available within the Investors & Media section of HOOKIPA’s
website at https://ir.hookipapharma.com/events. An archived replay
will be accessible for 30 days following the event.
About
HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a
clinical-stage biopharmaceutical company developing a new class
of immunotherapeutics based on its proprietary arenavirus
platform that reprograms the body’s immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, non-replicating and replicating, induce robust
antigen-specific CD8+ T cells and pathogen-neutralizing antibodies.
HOOKIPA’s viral vectors target antigen presenting cells in vivo to
activate the immune system. Both technologies enable repeat
administration to augment and refresh immune responses. Our
replicating arenavirus technology has the potential to induce
CD8+ T cell response levels previously not achieved by other
immuno-therapy approaches.
HOOKIPA is building a proprietary
immuno-oncology pipeline by targeting virally mediated cancer
antigens, self-antigens and next-generation antigens. The lead
replicating arenavirus oncology product candidates, HB-201 and
HB-202, are in development for the treatment of Human Papilloma
Virus 16-positive cancers in a Phase 1/2 clinical
trial.
HOOKIPA’s non-replicating
prophylactic Cytomegalovirus (CMV) vaccine candidate,
HB-101, is currently in a Phase 2 clinical trial for patients
awaiting kidney transplantation. To expand its infectious disease
portfolio, HOOKIPA entered into a collaboration and licensing
agreement with Gilead Sciences, Inc. to research arenavirus-based
functional cures for HIV and chronic hepatitis B
infections.
Find out more about HOOKIPA online
at www.hookipapharma.com.
For further information, please contact: |
Media |
Investors |
Nina
Waibel |
Matt
Beck |
Senior
Director - Communications |
Executive
Director - Investor Relations |
nina.waibel@hookipapharma.com |
matthew.beck@hookipapharma.com |
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Apr 2023 to Apr 2024